WCLC 2022 – Julia Rotow

Julia Rotow summarizes the achievements of EGFR tyrosine kinase inhibitors in the neoadjuvant therapy of lung cancer regarding multiple clinical outcomes, discusses if modification of the disease biology will be a feasible treatment goal in the setting of EGFR-directed neoadjuvant treatment sometime and talks about the individualization of neoadjuvant treatment of oncogene-driven lung cancer.

Here is the full WCLC 2022 report.